fbpx
Donate Toggle Menu

Attendees at the inaugural Advanced Urologic Cancer Consensus Conference (AUC3) met in Miami, Florida on January 23-24 to agree on optimal diagnostic and management strategies for kidney and bladder cancers.

“Tremendous progress has been made in the treatment of patients with advanced urologic cancers, but experts believe critical questions remain that are unable to be answered by robust prospective clinical trials. AUC3 aims to address this scarcity of information,” wrote organizers of the meeting, which included the conference organizers.

“KCA’s Board & Medical Steering Committee members participated in AUC3 to align on optimal diagnostic & management strategies for kidney & bladder cancer — working together to advance patient care,” said Gretchen E. Vaughan, KCA’s President and CEO. “By fostering collaboration among top experts, we help ensure the latest advancements reach all patients, especially those without access to leading specialists. This work is critical in propelling KCA’s mission to improve cancer care for everyone.”

Presenters and panelists helmed debates related to kidney cancer including topics such as adjuvant (pre-surgery) immunotherapy, additional rounds of immunotherapy even when a patients’ disease progresses, and genetic testing:

  • When should doctors re-challenge advanced renal cell carcinoma (RCC) patients with additional immunotherapy after their disease progresses?
  • When should patients with clear cell RCC be recommended adjuvant treatment with the immunotherapy pembrolizumab?
  • When is the correct time to introduce the novel nvel hypoxia-inducible factor 2a (HIF-2a) inhibitor belzutifan, which is currently approved to treat advanced RCC and is the only approved treatment for people with rare von Hippel-Lindau disease-associated RCC?
  • What is the role of genetic testing – specifically, next-generation sequencing and germline Next generation sequencing and germline testing – for RCC and non-clear cell RCC?
  • How does cytoreductive nephrectomy, which is surgery to remove a kidney tumor that has spread to other areas, fit into the current landscape of powerful combination drug therapies?

“Building consensus and guidance for the RCC field like this will save lives and advance research,” said Dr. Stephanie Berg, a medical oncologist at the Dana-Farber Cancer Institute. “Advocacy organizations like the Kidney Cancer Association can support patients and providers by helping to explain potential new guidance and how they reflect consensus from the top researchers and clinical providers in genitourinary oncology from around the world.”

Recent Blog Posts

image for blog post AUC3 Highlights

AUC3 Highlights

January 30, 2025

Attendees at the inaugural Advanced Urologic Cancer Consensus Conference (AUC3) met in Miami, Florida on January 23-24 to agree on…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *